Literature DB >> 7850781

Amplification at 12q13-14 in human malignant gliomas is frequently accompanied by loss of heterozygosity at loci proximal and distal to the amplification site.

G Reifenberger1, J Reifenberger, K Ichimura, V P Collins.   

Abstract

We have recently reported that a subset of human malignant gliomas shows amplification and overexpression of multiple genes from chromosomal segment 12q13-14, including CDK4, SAS, and MDM2. In the present study we have performed an allelotyping for 16 polymorphic loci spanning both arms of chromosome 12 in a series of 136 gliomas. Allelic deletions were found in 50% (7 of 14) of the malignant gliomas with 12q13-14 amplification and involved loci located on 12q proximal and distal to the amplification site. In contrast, the incidence of allelic loss on chromosome 12 was significantly lower in gliomas without 12q13-14 amplification [14% (11 of 79) in the WHO grade III and IV gliomas, 9% (4 of 43) in the WHO grade I and II gliomas]. The frequent association between 12q13-14 amplification and loss of alleles from 12q is in line with a model suggesting chromosome breakage and deletion as important events in the development of gene amplification.

Entities:  

Mesh:

Year:  1995        PMID: 7850781

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Brain tumours: classification and genes.

Authors:  V P Collins
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

2.  Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors.

Authors:  M Schiebe; P Ohneseit; W Hoffmann; R Meyermann; H P Rodemann; M Bamberg
Journal:  J Neurooncol       Date:  2000-09       Impact factor: 4.130

3.  Detrended fluctuation analysis of genome-wide copy number profiles of glioblastomas using array-based comparative genomic hybridization.

Authors:  Yukiko Nakahara; Tetsuya Shiraishi; Hiroaki Okamoto; Toshihiro Mineta; Tsuyoshi Oishi; Kohsuke Sasaki; Kazuo Tabuchi
Journal:  Neuro Oncol       Date:  2004-10       Impact factor: 12.300

4.  NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli.

Authors:  J Svaren; B R Sevetson; E D Apel; D B Zimonjic; N C Popescu; J Milbrandt
Journal:  Mol Cell Biol       Date:  1996-07       Impact factor: 4.272

Review 5.  Advances in the genetics of glioblastoma: are we reaching critical mass?

Authors:  Benjamin Purow; David Schiff
Journal:  Nat Rev Neurol       Date:  2009-07-14       Impact factor: 44.711

6.  Identification of novel candidate target genes in amplicons of Glioblastoma multiforme tumors detected by expression and CGH microarray profiling.

Authors:  Yolanda Ruano; Manuela Mollejo; Teresa Ribalta; Concepción Fiaño; Francisca I Camacho; Elena Gómez; Angel Rodríguez de Lope; Jose-Luis Hernández-Moneo; Pedro Martínez; Bárbara Meléndez
Journal:  Mol Cancer       Date:  2006-09-26       Impact factor: 27.401

7.  Small-cell lung cancer is characterized by a high incidence of deletions on chromosomes 3p, 4q, 5q, 10q, 13q and 17p.

Authors:  I Petersen; H Langreck; G Wolf; A Schwendel; R Psille; P Vogt; M B Reichel; T Ried; M Dietel
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Novel candidate key drivers in the integrative network of genes, microRNAs, methylations, and copy number variations in squamous cell lung carcinoma.

Authors:  Tao Huang; Jing Yang; Yu-Dong Cai
Journal:  Biomed Res Int       Date:  2015-02-23       Impact factor: 3.411

Review 9.  The roles of PIKE in tumorigenesis.

Authors:  Qi Qi; Keqiang Ye
Journal:  Acta Pharmacol Sin       Date:  2013-06-17       Impact factor: 6.150

10.  Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.

Authors:  Lawrence M Gelbert; Shufen Cai; Xi Lin; Concepcion Sanchez-Martinez; Miriam Del Prado; Maria Jose Lallena; Raquel Torres; Rose T Ajamie; Graham N Wishart; Robert Steven Flack; Blake Lee Neubauer; Jamie Young; Edward M Chan; Philip Iversen; Damien Cronier; Emiko Kreklau; Alfonso de Dios
Journal:  Invest New Drugs       Date:  2014-06-13       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.